HRP20241378T1 - Karboksi derivati s protuupalnim svojstvima - Google Patents

Info

Publication number

HRP20241378T1

HRP20241378T1 HRP20241378TT HRP20241378T HRP20241378T1 HR P20241378 T1 HRP20241378 T1 HR P20241378T1 HR P20241378T T HRP20241378T T HR P20241378TT HR P20241378 T HRP20241378 T HR P20241378T HR P20241378 T1 HRP20241378 T1 HR P20241378T1

Authority

HR

Croatia

Prior art keywords

methyl

acrylic acid

oxadiazol

phenyl

cyclopropyl

Prior art date

2019-12-23

Links

• Espacenet
• Global Dossier
• Discuss

• 230000003110 anti-inflammatory effect Effects 0.000 title 1
• 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims 32
• 150000003839 salts Chemical class 0.000 claims 31
• 239000012453 solvate Substances 0.000 claims 20
• 125000005843 halogen group Chemical group 0.000 claims 11
• 239000008194 pharmaceutical composition Substances 0.000 claims 10
• 239000003795 chemical substances by application Substances 0.000 claims 9
• 239000003112 inhibitor Substances 0.000 claims 9
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
• 125000000217 alkyl group Chemical group 0.000 claims 6
• 208000011580 syndromic disease Diseases 0.000 claims 6
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
• 230000001363 autoimmune Effects 0.000 claims 5
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
• 238000002560 therapeutic procedure Methods 0.000 claims 5
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 4
• 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 4
• 230000001684 chronic effect Effects 0.000 claims 4
• 125000004093 cyano group Chemical group *C#N 0.000 claims 4
• 208000035475 disorder Diseases 0.000 claims 4
• 125000001424 substituent group Chemical group 0.000 claims 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
• -1 2-((4-octylpyridin-2-yl)methyl)acrylic acid trifluoroacetic acid salt Chemical compound 0.000 claims 3
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 3
• NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 3
• 108010028006 B-Cell Activating Factor Proteins 0.000 claims 3
• 208000015943 Coeliac disease Diseases 0.000 claims 3
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 3
• 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 3
• 206010061218 Inflammation Diseases 0.000 claims 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
• 206010034277 Pemphigoid Diseases 0.000 claims 3
• 230000001154 acute effect Effects 0.000 claims 3
• 125000003545 alkoxy group Chemical group 0.000 claims 3
• 210000003719 b-lymphocyte Anatomy 0.000 claims 3
• 210000004027 cell Anatomy 0.000 claims 3
• 201000010099 disease Diseases 0.000 claims 3
• 208000024908 graft versus host disease Diseases 0.000 claims 3
• 125000004438 haloalkoxy group Chemical group 0.000 claims 3
• 125000001188 haloalkyl group Chemical group 0.000 claims 3
• 208000027866 inflammatory disease Diseases 0.000 claims 3
• 230000004054 inflammatory process Effects 0.000 claims 3
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
• 108020003175 receptors Proteins 0.000 claims 3
• 102000005962 receptors Human genes 0.000 claims 3
• 230000008685 targeting Effects 0.000 claims 3
• RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 2
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
• KSCMHTKJFWCRHJ-UHFFFAOYSA-N 2-[[3-(4-butoxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C KSCMHTKJFWCRHJ-UHFFFAOYSA-N 0.000 claims 2
• IPOUXAUBCPEGIH-UHFFFAOYSA-N 2-[[3-[(4-butylphenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 IPOUXAUBCPEGIH-UHFFFAOYSA-N 0.000 claims 2
• MXXULZUUXSJBAN-UHFFFAOYSA-N 2-[[3-[1-(4-bromophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound BrC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C MXXULZUUXSJBAN-UHFFFAOYSA-N 0.000 claims 2
• ANDQEQFQFGKZHR-UHFFFAOYSA-N 2-[[3-[1-[4-(pentafluoro-lambda6-sulfanyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FS(C1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)(F)(F)(F)F ANDQEQFQFGKZHR-UHFFFAOYSA-N 0.000 claims 2
• XBAYZCYLMGAAOC-UHFFFAOYSA-N 2-[[3-[1-[4-(trifluoromethylsulfanyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(SC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F XBAYZCYLMGAAOC-UHFFFAOYSA-N 0.000 claims 2
• QCHGAHDZXDQDCP-UHFFFAOYSA-N 2-[[3-[4-(pentafluoro-lambda6-sulfanyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FS(C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)(F)(F)(F)F QCHGAHDZXDQDCP-UHFFFAOYSA-N 0.000 claims 2
• XKFOEZLFLIDKMU-UHFFFAOYSA-N 2-[[5-[(4-chlorophenyl)-difluoromethyl]-1,2,4-oxadiazol-3-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C(C1=NC(=NO1)CC(C(=O)O)=C)(F)F XKFOEZLFLIDKMU-UHFFFAOYSA-N 0.000 claims 2
• MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 2
• 208000023769 AA amyloidosis Diseases 0.000 claims 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
• 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 2
• 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
• 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
• 201000003274 CINCA syndrome Diseases 0.000 claims 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
• 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims 2
• 206010010741 Conjunctivitis Diseases 0.000 claims 2
• 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 2
• 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 claims 2
• 201000004624 Dermatitis Diseases 0.000 claims 2
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
• 206010013774 Dry eye Diseases 0.000 claims 2
• 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 2
• 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
• 208000035690 Familial cold urticaria Diseases 0.000 claims 2
• 208000007465 Giant cell arteritis Diseases 0.000 claims 2
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 2
• 102000006395 Globulins Human genes 0.000 claims 2
• 108010044091 Globulins Proteins 0.000 claims 2
• 206010019939 Herpes gestationis Diseases 0.000 claims 2
• 241000725303 Human immunodeficiency virus Species 0.000 claims 2
• 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims 2
• 206010020751 Hypersensitivity Diseases 0.000 claims 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
• 206010022941 Iridocyclitis Diseases 0.000 claims 2
• 102000015617 Janus Kinases Human genes 0.000 claims 2
• 108010024121 Janus Kinases Proteins 0.000 claims 2
• 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
• 208000011200 Kawasaki disease Diseases 0.000 claims 2
• 208000028226 Krabbe disease Diseases 0.000 claims 2
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 2
• 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 2
• 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 2
• 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 2
• 208000009525 Myocarditis Diseases 0.000 claims 2
• 206010067472 Organising pneumonia Diseases 0.000 claims 2
• 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims 2
• 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 2
• 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 claims 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
• 201000004681 Psoriasis Diseases 0.000 claims 2
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
• 206010037660 Pyrexia Diseases 0.000 claims 2
• 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 2
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
• 206010052779 Transplant rejections Diseases 0.000 claims 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
• 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 claims 2
• 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
• 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
• 206010046851 Uveitis Diseases 0.000 claims 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
• 206010047115 Vasculitis Diseases 0.000 claims 2
• 208000027094 acute motor and sensory axonal neuropathy Diseases 0.000 claims 2
• 208000027137 acute motor axonal neuropathy Diseases 0.000 claims 2
• 125000000304 alkynyl group Chemical group 0.000 claims 2
• 208000026935 allergic disease Diseases 0.000 claims 2
• 201000004612 anterior uveitis Diseases 0.000 claims 2
• 230000001494 anti-thymocyte effect Effects 0.000 claims 2
• 201000008937 atopic dermatitis Diseases 0.000 claims 2
• 208000010668 atopic eczema Diseases 0.000 claims 2
• 125000004432 carbon atom Chemical group C* 0.000 claims 2
• 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
• 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims 2
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 206010014599 encephalitis Diseases 0.000 claims 2
• 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 2
• 125000001072 heteroaryl group Chemical group 0.000 claims 2
• 125000000623 heterocyclic group Chemical group 0.000 claims 2
• 230000007062 hydrolysis Effects 0.000 claims 2
• 238000006460 hydrolysis reaction Methods 0.000 claims 2
• 230000009610 hypersensitivity Effects 0.000 claims 2
• 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 2
• 230000028993 immune response Effects 0.000 claims 2
• 208000015181 infectious disease Diseases 0.000 claims 2
• 230000002757 inflammatory effect Effects 0.000 claims 2
• 230000000366 juvenile effect Effects 0.000 claims 2
• 206010063344 microscopic polyangiitis Diseases 0.000 claims 2
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 2
• 206010065579 multifocal motor neuropathy Diseases 0.000 claims 2
• 201000001119 neuropathy Diseases 0.000 claims 2
• 230000007823 neuropathy Effects 0.000 claims 2
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
• 208000033808 peripheral neuropathy Diseases 0.000 claims 2
• 229960003387 progesterone Drugs 0.000 claims 2
• 239000000186 progesterone Substances 0.000 claims 2
• 201000007798 pustular psoriasis 14 Diseases 0.000 claims 2
• 208000004644 retinal vein occlusion Diseases 0.000 claims 2
• 201000005671 spondyloarthropathy Diseases 0.000 claims 2
• 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 2
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
• 230000009885 systemic effect Effects 0.000 claims 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
• 206010043207 temporal arteritis Diseases 0.000 claims 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
• 102000003390 tumor necrosis factor Human genes 0.000 claims 2
• RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 2
• 229960001661 ursodiol Drugs 0.000 claims 2
• YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims 1
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
• 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
• 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
• BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
• YJWKQZKHPRCDCS-UHFFFAOYSA-N 2-[(3-cycloheptyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C1(CCCCCC1)C1=NOC(=N1)CC(C(=O)O)=C YJWKQZKHPRCDCS-UHFFFAOYSA-N 0.000 claims 1
• DMEDLJNQDIWYHB-UHFFFAOYSA-N 2-[(3-cyclohexyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C1(CCCCC1)C1=NOC(=N1)CC(C(=O)O)=C DMEDLJNQDIWYHB-UHFFFAOYSA-N 0.000 claims 1
• WWKFRXPVBBUVMY-UHFFFAOYSA-N 2-[(3-cyclooctyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C1(CCCCCCC1)C1=NOC(=N1)CC(C(=O)O)=C WWKFRXPVBBUVMY-UHFFFAOYSA-N 0.000 claims 1
• GDVQXNIGPNNLRD-UHFFFAOYSA-N 2-[(3-nonyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCCC)C1=NOC(=N1)CC(C(=O)O)=C GDVQXNIGPNNLRD-UHFFFAOYSA-N 0.000 claims 1
• XHGHQGWWJGBTOW-UHFFFAOYSA-N 2-[(3-oct-3-ynyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C(CC#CCCCC)C1=NOC(=N1)CC(C(=O)O)=C XHGHQGWWJGBTOW-UHFFFAOYSA-N 0.000 claims 1
• AYCVWQFTTHGTBH-UHFFFAOYSA-N 2-[(3-oct-7-ynyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCC#C)C1=NOC(=N1)CC(C(=O)O)=C AYCVWQFTTHGTBH-UHFFFAOYSA-N 0.000 claims 1
• JFQVEGQTUVGKSY-UHFFFAOYSA-N 2-[(3-octan-2-yl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound CC(CCCCCC)C1=NOC(=N1)CC(C(=O)O)=C JFQVEGQTUVGKSY-UHFFFAOYSA-N 0.000 claims 1
• ZUKFBHPVYIOEEG-UHFFFAOYSA-N 2-[(3-octyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCC)C1=NOC(=N1)CC(C(=O)O)=C ZUKFBHPVYIOEEG-UHFFFAOYSA-N 0.000 claims 1
• HQNIYWZYASCJCL-UHFFFAOYSA-N 2-[(3-undecyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCCCCC)C1=NOC(=N1)CC(C(=O)O)=C HQNIYWZYASCJCL-UHFFFAOYSA-N 0.000 claims 1
• MDCSOFJAPKZXTB-UHFFFAOYSA-N 2-[(4,5-dibutyl-1,3-oxazol-2-yl)methyl]prop-2-enoic acid Chemical compound C(CCC)C=1N=C(OC=1CCCC)CC(C(=O)O)=C MDCSOFJAPKZXTB-UHFFFAOYSA-N 0.000 claims 1
• CVMWJOARFZVMTB-UHFFFAOYSA-N 2-[(4-octyl-1,3-oxazol-2-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCC)C=1N=C(OC=1)CC(C(=O)O)=C CVMWJOARFZVMTB-UHFFFAOYSA-N 0.000 claims 1
• VINPNCPPRVDALI-UHFFFAOYSA-N 2-[(5-methyl-4-octyl-1,3-oxazol-2-yl)methyl]prop-2-enoic acid Chemical compound CC1=C(N=C(O1)CC(C(=O)O)=C)CCCCCCCC VINPNCPPRVDALI-UHFFFAOYSA-N 0.000 claims 1
• IECGQSROBXYODT-UHFFFAOYSA-N 2-[(5-octyl-1,2-oxazol-3-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCC)C1=CC(=NO1)CC(C(=O)O)=C IECGQSROBXYODT-UHFFFAOYSA-N 0.000 claims 1
• KGSNJGNAUJCVKJ-UHFFFAOYSA-N 2-[(5-octyl-1,3-thiazol-2-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCC)C1=CN=C(S1)CC(C(=O)O)=C KGSNJGNAUJCVKJ-UHFFFAOYSA-N 0.000 claims 1
• RKGYURZPLQRBFO-UHFFFAOYSA-N 2-[(5-octylpyrazin-2-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCC)C=1N=CC(=NC=1)CC(C(=O)O)=C RKGYURZPLQRBFO-UHFFFAOYSA-N 0.000 claims 1
• TYYWEYHTZVWXLQ-UHFFFAOYSA-N 2-[(5-octylpyridin-2-yl)methyl]prop-2-enoic acid 2,2,2-trifluoroacetic acid Chemical compound CCCCCCCCC1=CN=C(C=C1)CC(=C)C(=O)O.C(=O)(C(F)(F)F)O TYYWEYHTZVWXLQ-UHFFFAOYSA-N 0.000 claims 1
• QXJBOWNYFABBIB-UHFFFAOYSA-N 2-[(5-octylpyrimidin-2-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCC)C=1C=NC(=NC=1)CC(C(=O)O)=C QXJBOWNYFABBIB-UHFFFAOYSA-N 0.000 claims 1
• DWRYTFDPPJLVCM-UHFFFAOYSA-N 2-[(6-octylpyridazin-3-yl)methyl]prop-2-enoic acid Chemical compound C(CCCCCCC)C1=CC=C(N=N1)CC(C(=O)O)=C DWRYTFDPPJLVCM-UHFFFAOYSA-N 0.000 claims 1
• NYGMBNIJQOPMIR-UHFFFAOYSA-N 2-[1-[3-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]cyclopropyl]prop-2-enoic acid Chemical compound FC(C1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)C1(CC1)C(C(=O)O)=C)(F)F NYGMBNIJQOPMIR-UHFFFAOYSA-N 0.000 claims 1
• HRRKMHFHSHTDBZ-UHFFFAOYSA-N 2-[1-[3-[difluoro-[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]cyclopropyl]prop-2-enoic acid Chemical compound FC(C1=NOC(=N1)C1(CC1)C(C(=O)O)=C)(C1=CC=C(C=C1)C(F)(F)F)F HRRKMHFHSHTDBZ-UHFFFAOYSA-N 0.000 claims 1
• ZUKFBHPVYIOEEG-RORPREDISA-N 2-[[3-(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecadeuteriooctyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(C(C(C(C(C(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])(C1=NOC(=N1)CC(C(=O)O)=C)([2H])[2H] ZUKFBHPVYIOEEG-RORPREDISA-N 0.000 claims 1
• ORYDFCWSCHWSKL-UHFFFAOYSA-N 2-[[3-(2-methylheptan-2-yl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound CC(C)(CCCCC)C1=NOC(=N1)CC(C(=O)O)=C ORYDFCWSCHWSKL-UHFFFAOYSA-N 0.000 claims 1
• OFEVAOWTQPYJRQ-UHFFFAOYSA-N 2-[[3-(2-methyloctan-2-yl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound CC(C)(CCCCCC)C1=NOC(=N1)CC(C(=O)O)=C OFEVAOWTQPYJRQ-UHFFFAOYSA-N 0.000 claims 1
• UNVWBDWBTYOLQR-UHFFFAOYSA-N 2-[[3-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=CC=1OCCC)C1=NOC(=N1)CC(C(=O)O)=C UNVWBDWBTYOLQR-UHFFFAOYSA-N 0.000 claims 1
• OKMUVCIAJLPCKG-UHFFFAOYSA-N 2-[[3-(4,6-dichloro-2,3-dihydro-1H-inden-1-yl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=C2CCC(C2=CC(=C1)Cl)C1=NOC(=N1)CC(C(=O)O)=C OKMUVCIAJLPCKG-UHFFFAOYSA-N 0.000 claims 1
• WVBHZKSZRYNFKG-UHFFFAOYSA-N 2-[[3-(4-butoxy-3,5-difluorophenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=C(C=C(C=C1F)C1=NOC(=N1)CC(C(=O)O)=C)F WVBHZKSZRYNFKG-UHFFFAOYSA-N 0.000 claims 1
• JBQFMFAJLBCHKZ-UHFFFAOYSA-N 2-[[3-(4-butoxy-3-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=C(C=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)Cl JBQFMFAJLBCHKZ-UHFFFAOYSA-N 0.000 claims 1
• NSCDNSABHJYRCY-UHFFFAOYSA-N 2-[[3-(4-butoxy-3-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=C(C=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)F NSCDNSABHJYRCY-UHFFFAOYSA-N 0.000 claims 1
• BLFGJSOTPFKXNT-UHFFFAOYSA-N 2-[[3-(4-butylphenoxy)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C1=CC=C(OC2=NOC(=N2)CC(C(=O)O)=C)C=C1 BLFGJSOTPFKXNT-UHFFFAOYSA-N 0.000 claims 1
• ITDAOQDLLUGZFB-UHFFFAOYSA-N 2-[[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C ITDAOQDLLUGZFB-UHFFFAOYSA-N 0.000 claims 1
• DXPSFNGJUSJZKI-UHFFFAOYSA-N 2-[[3-(4-cyclobutyloxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C1(CCC1)OC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C DXPSFNGJUSJZKI-UHFFFAOYSA-N 0.000 claims 1
• JHMVESAZFWYLLQ-UHFFFAOYSA-N 2-[[3-(4-cyclopentyloxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C1(CCCC1)OC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C JHMVESAZFWYLLQ-UHFFFAOYSA-N 0.000 claims 1
• XPKSBYYUZKMILE-UHFFFAOYSA-N 2-[[3-(4-iodophenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound IC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C XPKSBYYUZKMILE-UHFFFAOYSA-N 0.000 claims 1
• SOMSYBFZRQOHSF-UHFFFAOYSA-N 2-[[3-(4-pentylphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCCC)C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C SOMSYBFZRQOHSF-UHFFFAOYSA-N 0.000 claims 1
• ODKQNFDGMMDEBI-UHFFFAOYSA-N 2-[[3-(4-phenylmethoxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C ODKQNFDGMMDEBI-UHFFFAOYSA-N 0.000 claims 1
• CXBKFBKSIOWPGT-UHFFFAOYSA-N 2-[[3-(4-propoxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CC)OC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C CXBKFBKSIOWPGT-UHFFFAOYSA-N 0.000 claims 1
• CVROVWJTTSUJMF-UHFFFAOYSA-N 2-[[3-(4-pyrrolidin-1-ylphenyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound N1(CCCC1)C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C CVROVWJTTSUJMF-UHFFFAOYSA-N 0.000 claims 1
• RNWMINOESLCQJT-UHFFFAOYSA-N 2-[[3-(6-methylheptyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound CC(CCCCCC1=NOC(=N1)CC(C(=O)O)=C)C RNWMINOESLCQJT-UHFFFAOYSA-N 0.000 claims 1
• JNPYKJWUOBULDS-UHFFFAOYSA-N 2-[[3-(7,7,8,8,8-pentafluorooctyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCCCCC1=NOC(=N1)CC(C(=O)O)=C)(C(F)(F)F)F JNPYKJWUOBULDS-UHFFFAOYSA-N 0.000 claims 1
• XBSUGBPIFXAIAX-UHFFFAOYSA-N 2-[[3-(7,7,8-trifluorooctyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCCCCC1=NOC(=N1)CC(C(=O)O)=C)(CF)F XBSUGBPIFXAIAX-UHFFFAOYSA-N 0.000 claims 1
• DEARRKNFZIAKDM-UHFFFAOYSA-N 2-[[3-(8,8,8-trifluorooctan-2-yl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCCCC(C)C1=NOC(=N1)CC(C(=O)O)=C)(F)F DEARRKNFZIAKDM-UHFFFAOYSA-N 0.000 claims 1
• VUFZPBQQDZIKKH-UHFFFAOYSA-N 2-[[3-(8,8,8-trifluorooctyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCCCCCC1=NOC(=N1)CC(C(=O)O)=C)(F)F VUFZPBQQDZIKKH-UHFFFAOYSA-N 0.000 claims 1
• OIDIJKAFDFJUNX-UHFFFAOYSA-N 2-[[3-(cyclohexylmethyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C1(CCCCC1)CC1=NOC(=N1)CC(C(=O)O)=C OIDIJKAFDFJUNX-UHFFFAOYSA-N 0.000 claims 1
• BCQLFHLORGEIPO-UHFFFAOYSA-N 2-[[3-(naphthalen-2-ylmethyl)-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)CC1=NOC(=N1)CC(C(=O)O)=C BCQLFHLORGEIPO-UHFFFAOYSA-N 0.000 claims 1
• JFQVEGQTUVGKSY-SNVBAGLBSA-N 2-[[3-[(2R)-octan-2-yl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C[C@H](CCCCCC)C1=NOC(=N1)CC(C(=O)O)=C JFQVEGQTUVGKSY-SNVBAGLBSA-N 0.000 claims 1
• JFQVEGQTUVGKSY-JTQLQIEISA-N 2-[[3-[(2S)-octan-2-yl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C[C@@H](CCCCCC)C1=NOC(=N1)CC(C(=O)O)=C JFQVEGQTUVGKSY-JTQLQIEISA-N 0.000 claims 1
• ZBLVCSRSFBGWKU-UHFFFAOYSA-N 2-[[3-[(3,4-dichlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=CC=1Cl ZBLVCSRSFBGWKU-UHFFFAOYSA-N 0.000 claims 1
• XWOWBSSJDUUYOG-UHFFFAOYSA-N 2-[[3-[(3,5-dichloro-4-fluorophenyl)-difluoromethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=C(C=1F)Cl)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F XWOWBSSJDUUYOG-UHFFFAOYSA-N 0.000 claims 1
• GAGBXJFJTWUPMO-UHFFFAOYSA-N 2-[[3-[(3,5-dichloro-4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C(C=1F)Cl GAGBXJFJTWUPMO-UHFFFAOYSA-N 0.000 claims 1
• MHVCXSKUJFKOQI-UHFFFAOYSA-N 2-[[3-[(3,5-dichlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C(C=1)Cl MHVCXSKUJFKOQI-UHFFFAOYSA-N 0.000 claims 1
• ANKDURUUGDNUKN-UHFFFAOYSA-N 2-[[3-[(3-butylphenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C=1C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=CC=1 ANKDURUUGDNUKN-UHFFFAOYSA-N 0.000 claims 1
• XTMCGYKFSHIRQQ-UHFFFAOYSA-N 2-[[3-[(3-chloro-4-methoxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=CC=1OC XTMCGYKFSHIRQQ-UHFFFAOYSA-N 0.000 claims 1
• LKWADTFRKPGHLB-UHFFFAOYSA-N 2-[[3-[(3-chloro-4-methylphenyl)-difluoromethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=CC=1C)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F LKWADTFRKPGHLB-UHFFFAOYSA-N 0.000 claims 1
• QVOBIOAFDZISLP-UHFFFAOYSA-N 2-[[3-[(3-chloro-4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=CC=1C QVOBIOAFDZISLP-UHFFFAOYSA-N 0.000 claims 1
• FJCJRBOYJZGTDV-UHFFFAOYSA-N 2-[[3-[(4-bromo-3-chlorophenyl)-difluoromethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound BrC1=C(C=C(C=C1)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F)Cl FJCJRBOYJZGTDV-UHFFFAOYSA-N 0.000 claims 1
• LEQQPCQFZUJRGP-UHFFFAOYSA-N 2-[[3-[(4-bromo-3-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound BrC1=C(C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1)Cl LEQQPCQFZUJRGP-UHFFFAOYSA-N 0.000 claims 1
• GXLVWVFZSLCMJS-UHFFFAOYSA-N 2-[[3-[(4-bromophenyl)-difluoromethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound BrC1=CC=C(C=C1)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F GXLVWVFZSLCMJS-UHFFFAOYSA-N 0.000 claims 1
• XGDASGQRLNJAMF-UHFFFAOYSA-N 2-[[3-[(4-butoxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 XGDASGQRLNJAMF-UHFFFAOYSA-N 0.000 claims 1
• IVKDJKAYLBNSRL-UHFFFAOYSA-N 2-[[3-[(4-butylphenyl)-difluoromethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C1=CC=C(C=C1)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F IVKDJKAYLBNSRL-UHFFFAOYSA-N 0.000 claims 1
• RZVFQPVTKAZAED-UHFFFAOYSA-N 2-[[3-[(4-chloro-3,5-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=C(C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1F)F RZVFQPVTKAZAED-UHFFFAOYSA-N 0.000 claims 1
• NVLOYQVZJAEDDG-UHFFFAOYSA-N 2-[[3-[(4-chlorophenyl)-difluoromethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F NVLOYQVZJAEDDG-UHFFFAOYSA-N 0.000 claims 1
• GJPNGWITFUFPJB-UHFFFAOYSA-N 2-[[3-[(4-chlorophenyl)-fluoromethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C(C1=NOC(=N1)CC(C(=O)O)=C)F GJPNGWITFUFPJB-UHFFFAOYSA-N 0.000 claims 1
• YWEVHXUOROVDGP-UHFFFAOYSA-N 2-[[3-[(4-propylphenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CC)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 YWEVHXUOROVDGP-UHFFFAOYSA-N 0.000 claims 1
• AYAFSWZPFZVPGY-UHFFFAOYSA-N 2-[[3-[(4-tert-butylphenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(C)(C)(C)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 AYAFSWZPFZVPGY-UHFFFAOYSA-N 0.000 claims 1
• RWZKCUQHYRKBPZ-UHFFFAOYSA-N 2-[[3-[1-(2-chlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=C(C=CC=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C RWZKCUQHYRKBPZ-UHFFFAOYSA-N 0.000 claims 1
• QXTIPOZICIFENS-UHFFFAOYSA-N 2-[[3-[1-(3,5-dichloro-4-fluorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=C(C=1F)Cl)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C QXTIPOZICIFENS-UHFFFAOYSA-N 0.000 claims 1
• HMRXLBHHIWJBOQ-UHFFFAOYSA-N 2-[[3-[1-(3-chloro-4-methoxyphenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=CC=1OC)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C HMRXLBHHIWJBOQ-UHFFFAOYSA-N 0.000 claims 1
• BJBYAXAZFARKMF-UHFFFAOYSA-N 2-[[3-[1-(3-chloro-4-methylphenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=CC=1C)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C BJBYAXAZFARKMF-UHFFFAOYSA-N 0.000 claims 1
• GNCWAQCCMVLWSH-UHFFFAOYSA-N 2-[[3-[1-(3-chlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=CC=1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C GNCWAQCCMVLWSH-UHFFFAOYSA-N 0.000 claims 1
• BMWHFYDBEMBKMQ-UHFFFAOYSA-N 2-[[3-[1-(4-bromo-3,5-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound BrC1=C(C=C(C=C1Cl)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)Cl BMWHFYDBEMBKMQ-UHFFFAOYSA-N 0.000 claims 1
• YWCCYLKOCAQPOX-UHFFFAOYSA-N 2-[[3-[1-(4-bromo-3-chlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound BrC1=C(C=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)Cl YWCCYLKOCAQPOX-UHFFFAOYSA-N 0.000 claims 1
• ZAAHIUSUTXWILS-UHFFFAOYSA-N 2-[[3-[1-(4-butoxyphenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C ZAAHIUSUTXWILS-UHFFFAOYSA-N 0.000 claims 1
• WPDUBIKPIXCGQS-UHFFFAOYSA-N 2-[[3-[1-(4-chloro-3,5-difluorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=C(C=C(C=C1F)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)F WPDUBIKPIXCGQS-UHFFFAOYSA-N 0.000 claims 1
• YJIBCTLHCIVRRZ-UHFFFAOYSA-N 2-[[3-[1-(4-chloro-3-fluorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=C(C=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)F YJIBCTLHCIVRRZ-UHFFFAOYSA-N 0.000 claims 1
• BGAHYZSZQVXXRU-UHFFFAOYSA-N 2-[[3-[1-(4-chlorophenyl)cyclobutyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C1(CCC1)C1=NOC(=N1)CC(C(=O)O)=C BGAHYZSZQVXXRU-UHFFFAOYSA-N 0.000 claims 1
• OEHNIQIEHULEOP-UHFFFAOYSA-N 2-[[3-[1-(4-chlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C OEHNIQIEHULEOP-UHFFFAOYSA-N 0.000 claims 1
• KOPUVXVTYKORND-UHFFFAOYSA-N 2-[[3-[1-(4-cyclobutylphenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C1(CCC1)C1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C KOPUVXVTYKORND-UHFFFAOYSA-N 0.000 claims 1
• PRZHLWIQKHVHPP-UHFFFAOYSA-N 2-[[3-[1-(4-cyclopropyloxyphenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C1(CC1)OC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C PRZHLWIQKHVHPP-UHFFFAOYSA-N 0.000 claims 1
• NDLCPDRMACMJRR-UHFFFAOYSA-N 2-[[3-[1-(4-fluorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C NDLCPDRMACMJRR-UHFFFAOYSA-N 0.000 claims 1
• ZQQVGIKLTWAKDG-UHFFFAOYSA-N 2-[[3-[1-(4-iodophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound IC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C ZQQVGIKLTWAKDG-UHFFFAOYSA-N 0.000 claims 1
• YFQGSNFZZANUSO-UHFFFAOYSA-N 2-[[3-[1-(4-methoxyphenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound COC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C YFQGSNFZZANUSO-UHFFFAOYSA-N 0.000 claims 1
• DJSIQRUGBHIZEV-UHFFFAOYSA-N 2-[[3-[1-[3-chloro-4-(trifluoromethyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(C=CC=1C(F)(F)F)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C DJSIQRUGBHIZEV-UHFFFAOYSA-N 0.000 claims 1
• PTXWXNAWOLSICD-UHFFFAOYSA-N 2-[[3-[1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(C(F)F)(OC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)F PTXWXNAWOLSICD-UHFFFAOYSA-N 0.000 claims 1
• LQWHMOBGCCFNCI-UHFFFAOYSA-N 2-[[3-[1-[4-(difluoromethoxy)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(OC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)F LQWHMOBGCCFNCI-UHFFFAOYSA-N 0.000 claims 1
• NPSPASPIBVTRGY-UHFFFAOYSA-N 2-[[3-[1-[4-(trifluoromethoxy)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(OC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F NPSPASPIBVTRGY-UHFFFAOYSA-N 0.000 claims 1
• HMJMIZFIWFCEMX-UHFFFAOYSA-N 2-[[3-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(C1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F HMJMIZFIWFCEMX-UHFFFAOYSA-N 0.000 claims 1
• BOJGYDWWSDUDEO-UHFFFAOYSA-N 2-[[3-[1-[4-(trifluoromethylsulfinyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(S(=O)C1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F BOJGYDWWSDUDEO-UHFFFAOYSA-N 0.000 claims 1
• CNBIDJBCAWLVNL-UHFFFAOYSA-N 2-[[3-[2-(4-chlorophenyl)ethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)CCC1=NOC(=N1)CC(C(=O)O)=C CNBIDJBCAWLVNL-UHFFFAOYSA-N 0.000 claims 1
• RZNNYDWOXWUJQG-UHFFFAOYSA-N 2-[[3-[2-(4-chlorophenyl)propan-2-yl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C(C)(C)C1=NOC(=N1)CC(C(=O)O)=C RZNNYDWOXWUJQG-UHFFFAOYSA-N 0.000 claims 1
• RXOCJZFGDPTMAH-UHFFFAOYSA-N 2-[[3-[2-(4-ethylphenyl)ethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(C)C1=CC=C(C=C1)CCC1=NOC(=N1)CC(C(=O)O)=C RXOCJZFGDPTMAH-UHFFFAOYSA-N 0.000 claims 1
• ILPFGDRJLZQGLG-UHFFFAOYSA-N 2-[[3-[2-(4-propylphenyl)ethyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CC)C1=CC=C(C=C1)CCC1=NOC(=N1)CC(C(=O)O)=C ILPFGDRJLZQGLG-UHFFFAOYSA-N 0.000 claims 1
• SGONZYICKKIQBF-UHFFFAOYSA-N 2-[[3-[3-(4-chlorophenyl)propyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)CCCC1=NOC(=N1)CC(C(=O)O)=C SGONZYICKKIQBF-UHFFFAOYSA-N 0.000 claims 1
• QQQQDBQYBKAIEM-UHFFFAOYSA-N 2-[[3-[4-(1,1-difluorobutyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCC)(F)C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C QQQQDBQYBKAIEM-UHFFFAOYSA-N 0.000 claims 1
• BVLPQTZGQQCBQS-UHFFFAOYSA-N 2-[[3-[4-(1,1-difluoropentyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCC)(F)C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C BVLPQTZGQQCBQS-UHFFFAOYSA-N 0.000 claims 1
• TXRVBOJTEATVRX-UHFFFAOYSA-N 2-[[3-[4-(1,1-difluoropropyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CC)(F)C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C TXRVBOJTEATVRX-UHFFFAOYSA-N 0.000 claims 1
• GOHXZYYMINJJAG-UHFFFAOYSA-N 2-[[3-[4-(1-propylcyclopropyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CC)C1(CC1)C1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C GOHXZYYMINJJAG-UHFFFAOYSA-N 0.000 claims 1
• CGZWCJWERYRBMV-UHFFFAOYSA-N 2-[[3-[4-(2-cyclopropylethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C1(CC1)CCC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C CGZWCJWERYRBMV-UHFFFAOYSA-N 0.000 claims 1
• SVSLWWYRGQDCKR-UHFFFAOYSA-N 2-[[3-[4-(3,3,3-trifluoropropyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F SVSLWWYRGQDCKR-UHFFFAOYSA-N 0.000 claims 1
• DTWKOGWKLCBDDA-UHFFFAOYSA-N 2-[[3-[4-(3-methoxypropoxy)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound COCCCOC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C DTWKOGWKLCBDDA-UHFFFAOYSA-N 0.000 claims 1
• ACGGZZLJZRONIP-UHFFFAOYSA-N 2-[[3-[4-(4,4,4-trifluorobutoxy)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCOC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F ACGGZZLJZRONIP-UHFFFAOYSA-N 0.000 claims 1
• SHKXYZFPAUNWJH-LLVKDONJSA-N 2-[[3-[4-[(2R)-butan-2-yl]oxyphenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound CC[C@@H](C)OC1=CC=C(C=C1)C2=NOC(=N2)CC(=C)C(=O)O SHKXYZFPAUNWJH-LLVKDONJSA-N 0.000 claims 1
• ZVNAQUSWOCVXAL-UHFFFAOYSA-N 2-[[3-[4-butoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=C(C=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)C(F)(F)F ZVNAQUSWOCVXAL-UHFFFAOYSA-N 0.000 claims 1
• BCRYVNLZVDKJFL-UHFFFAOYSA-N 2-[[3-[[3-chloro-4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC=1C=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=CC=1C(F)(F)F BCRYVNLZVDKJFL-UHFFFAOYSA-N 0.000 claims 1
• MZJRJBYPAWLVAG-UHFFFAOYSA-N 2-[[3-[[4-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(C(F)F)(OC1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1)F MZJRJBYPAWLVAG-UHFFFAOYSA-N 0.000 claims 1
• QPLBXCUGOJTZJP-UHFFFAOYSA-N 2-[[3-[[4-(1,1-difluoropentyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCC)(F)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 QPLBXCUGOJTZJP-UHFFFAOYSA-N 0.000 claims 1
• RGYDUWSDCYPLTL-UHFFFAOYSA-N 2-[[3-[[4-(1-propylcyclopropyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(CC)C1(CC1)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 RGYDUWSDCYPLTL-UHFFFAOYSA-N 0.000 claims 1
• WMFUXFIIQNOWNE-UHFFFAOYSA-N 2-[[3-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound C(C(C)(C)C)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 WMFUXFIIQNOWNE-UHFFFAOYSA-N 0.000 claims 1
• OLXCVYWHHFJOOX-UHFFFAOYSA-N 2-[[3-[[4-(4-chlorophenyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C1=CC=C(C=C1)CC1=NOC(=N1)CC(C(=O)O)=C OLXCVYWHHFJOOX-UHFFFAOYSA-N 0.000 claims 1
• ZDZWALIKCFUWNE-UHFFFAOYSA-N 2-[[3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(OC1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1)(F)F ZDZWALIKCFUWNE-UHFFFAOYSA-N 0.000 claims 1
• NOKTYYYDLUYPIU-UHFFFAOYSA-N 2-[[3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1)(F)F NOKTYYYDLUYPIU-UHFFFAOYSA-N 0.000 claims 1
• VWPHRPOFMKINSQ-UHFFFAOYSA-N 2-[[3-[[4-[1-(trifluoromethyl)cyclopropyl]phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(C1(CC1)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1)(F)F VWPHRPOFMKINSQ-UHFFFAOYSA-N 0.000 claims 1
• RFIDIECKBLFKNX-UHFFFAOYSA-N 2-[[3-[difluoro-(4-iodophenyl)methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(C1=NOC(=N1)CC(C(=O)O)=C)(C1=CC=C(C=C1)I)F RFIDIECKBLFKNX-UHFFFAOYSA-N 0.000 claims 1
• GMKHMMJLENCXAE-UHFFFAOYSA-N 2-[[3-[difluoro-[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]methyl]prop-2-enoic acid Chemical compound FC(C1=NOC(=N1)CC(C(=O)O)=C)(C1=CC=C(C=C1)C(F)(F)F)F GMKHMMJLENCXAE-UHFFFAOYSA-N 0.000 claims 1
• MEWIMDIPLNOYGN-UHFFFAOYSA-N 2-[[4-[(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)methyl]benzoyl]amino]-4-cyanobenzoic acid Chemical group Nc1nc2[nH]cc(Cc3ccc(cc3)C(=O)Nc3cc(ccc3C(O)=O)C#N)c2c(=O)[nH]1 MEWIMDIPLNOYGN-UHFFFAOYSA-N 0.000 claims 1
• WNMFPOMNDSBIDV-UHFFFAOYSA-N 2-[[4-[(4-butylphenyl)methyl]-1,3-oxazol-2-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C1=CC=C(CC=2N=C(OC=2)CC(C(=O)O)=C)C=C1 WNMFPOMNDSBIDV-UHFFFAOYSA-N 0.000 claims 1
• LWSKMMZRWXXVCA-UHFFFAOYSA-N 2-[[4-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]-1,3-oxazol-2-yl]methyl]prop-2-enoic acid Chemical compound FC(C1=CC=C(C=C1)C1(CC1)C=1N=C(OC=1)CC(C(=O)O)=C)(F)F LWSKMMZRWXXVCA-UHFFFAOYSA-N 0.000 claims 1
• UGDLZPCZTZFLSA-UHFFFAOYSA-N 2-[[5-(1,1-difluorooctyl)-1,2,4-oxadiazol-3-yl]methyl]prop-2-enoic acid Chemical compound FC(CCCCCCC)(F)C1=NC(=NO1)CC(C(=O)O)=C UGDLZPCZTZFLSA-UHFFFAOYSA-N 0.000 claims 1
• SFNTYGTZRZUXTN-UHFFFAOYSA-N 2-[[5-(4-butoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)OC1=CC=C(C=C1)C1=NC(=NO1)CC(C(=O)O)=C SFNTYGTZRZUXTN-UHFFFAOYSA-N 0.000 claims 1
• VAJCQJHDOGNAOX-UHFFFAOYSA-N 2-[[5-[(4-bromophenyl)-difluoromethyl]-1,2,4-oxadiazol-3-yl]methyl]prop-2-enoic acid Chemical compound BrC1=CC=C(C=C1)C(C1=NC(=NO1)CC(C(=O)O)=C)(F)F VAJCQJHDOGNAOX-UHFFFAOYSA-N 0.000 claims 1
• FTHHAPLJRSADIE-UHFFFAOYSA-N 2-[[5-[(4-butylphenyl)methyl]-1,2,4-oxadiazol-3-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C1=CC=C(CC2=NC(=NO2)CC(C(=O)O)=C)C=C1 FTHHAPLJRSADIE-UHFFFAOYSA-N 0.000 claims 1
• RIZZSEIAKVVJAL-UHFFFAOYSA-N 2-[[5-[difluoro-[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]methyl]prop-2-enoic acid Chemical compound FC(C1=NC(=NO1)CC(C(=O)O)=C)(C1=CC=C(C=C1)C(F)(F)F)F RIZZSEIAKVVJAL-UHFFFAOYSA-N 0.000 claims 1
• SCAFABDPOTYGIK-UHFFFAOYSA-N 2-[[5-butyl-4-(4-chlorophenyl)-1,3-oxazol-2-yl]methyl]prop-2-enoic acid Chemical compound C(CCC)C1=C(N=C(O1)CC(C(=O)O)=C)C1=CC=C(C=C1)Cl SCAFABDPOTYGIK-UHFFFAOYSA-N 0.000 claims 1
• VQDATRBILKPVFF-UHFFFAOYSA-N 2-[[6-[(4-chlorophenyl)methyl]pyridin-2-yl]methyl]prop-2-enoic acid 2,2,2-trifluoroacetic acid Chemical compound C=C(CC1=CC=CC(=N1)CC2=CC=C(C=C2)Cl)C(=O)O.C(=O)(C(F)(F)F)O VQDATRBILKPVFF-UHFFFAOYSA-N 0.000 claims 1
• DHGIHDCBJGUXAF-UHFFFAOYSA-N 2-[[6-[1-(4-chlorophenyl)cyclopropyl]pyridin-2-yl]methyl]prop-2-enoic acid Chemical compound ClC1=CC=C(C=C1)C1(CC1)C1=CC=CC(=N1)CC(C(=O)O)=C DHGIHDCBJGUXAF-UHFFFAOYSA-N 0.000 claims 1
• NVRJVVSEQYIIPZ-UHFFFAOYSA-N 2-[methoxy-(3-octyl-1,2,4-oxadiazol-5-yl)methyl]prop-2-enoic acid Chemical compound COC(C(C(=O)O)=C)C1=NC(=NO1)CCCCCCCC NVRJVVSEQYIIPZ-UHFFFAOYSA-N 0.000 claims 1
• BJEIDDCHDQVSRJ-UHFFFAOYSA-N 2-methylidene-3-[3-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]butanoic acid Chemical compound C=C(C(=O)O)C(C)C1=NC(=NO1)C1(CC1)C1=CC=C(C=C1)C(F)(F)F BJEIDDCHDQVSRJ-UHFFFAOYSA-N 0.000 claims 1
• HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 claims 1
• JCESOHWLSWOLKO-UHFFFAOYSA-N 3-methyl-2-methylidene-3-[3-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]-1,2,4-oxadiazol-5-yl]butanoic acid Chemical compound CC(C(C(=O)O)=C)(C)C1=NC(=NO1)C1(CC1)C1=CC=C(C=C1)C(F)(F)F JCESOHWLSWOLKO-UHFFFAOYSA-N 0.000 claims 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims 1
• 206010000503 Acne cystic Diseases 0.000 claims 1
• 208000026872 Addison Disease Diseases 0.000 claims 1
• 102100025976 Adenosine deaminase 2 Human genes 0.000 claims 1
• 101710142940 Adenosine deaminase 2 Proteins 0.000 claims 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
• 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
• 208000033237 Aicardi-Goutières syndrome Diseases 0.000 claims 1
• 208000011403 Alexander disease Diseases 0.000 claims 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
• 206010001935 American trypanosomiasis Diseases 0.000 claims 1
• 206010002383 Angina Pectoris Diseases 0.000 claims 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
• 208000008958 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Diseases 0.000 claims 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
• 208000001839 Antisynthetase syndrome Diseases 0.000 claims 1
• 206010002921 Aortitis Diseases 0.000 claims 1
• 206010003178 Arterial thrombosis Diseases 0.000 claims 1
• 206010053555 Arthritis bacterial Diseases 0.000 claims 1
• 206010003267 Arthritis reactive Diseases 0.000 claims 1
• 206010003402 Arthropod sting Diseases 0.000 claims 1
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
• 206010069002 Autoimmune pancreatitis Diseases 0.000 claims 1
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
• 102100036465 Autoimmune regulator Human genes 0.000 claims 1
• 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 1
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 1
• 229940122314 B-cell activating factor inhibitor Drugs 0.000 claims 1
• 229940125814 BTK kinase inhibitor Drugs 0.000 claims 1
• 208000023328 Basedow disease Diseases 0.000 claims 1
• 208000027496 Behcet disease Diseases 0.000 claims 1
• 208000009137 Behcet syndrome Diseases 0.000 claims 1
• 208000017306 Bickerstaff brainstem encephalitis Diseases 0.000 claims 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
• 208000003014 Bites and Stings Diseases 0.000 claims 1
• 208000009766 Blau syndrome Diseases 0.000 claims 1
• RYDQCOKATXUTDR-UHFFFAOYSA-N BrC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound BrC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C RYDQCOKATXUTDR-UHFFFAOYSA-N 0.000 claims 1
• 206010006458 Bronchitis chronic Diseases 0.000 claims 1
• IYOKYXZSPPPOBB-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C=1N=C(OC=1)CC(C(=O)O)=C Chemical compound C(CCC)C1=CC=C(C=C1)C=1N=C(OC=1)CC(C(=O)O)=C IYOKYXZSPPPOBB-UHFFFAOYSA-N 0.000 claims 1
• JRAHUTLJTBZQLE-UHFFFAOYSA-N C(CCC)C=1C=C(C=CC=1)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound C(CCC)C=1C=C(C=CC=1)C1=NOC(=N1)CC(C(=O)O)=C JRAHUTLJTBZQLE-UHFFFAOYSA-N 0.000 claims 1
• KEGLLBFPLANSLF-UHFFFAOYSA-N C(CCCC)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 Chemical compound C(CCCC)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 KEGLLBFPLANSLF-UHFFFAOYSA-N 0.000 claims 1
• RVWODTYXUFJTTD-UHFFFAOYSA-N C(CCCCCC)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound C(CCCCCC)C1=NOC(=N1)CC(C(=O)O)=C RVWODTYXUFJTTD-UHFFFAOYSA-N 0.000 claims 1
• DZTSJEHCICDUSW-UHFFFAOYSA-N C(CCCCCCC)C1=CN=C(O1)CC(C(=O)O)=C Chemical compound C(CCCCCCC)C1=CN=C(O1)CC(C(=O)O)=C DZTSJEHCICDUSW-UHFFFAOYSA-N 0.000 claims 1
• TWSJVBWHYGITRA-UHFFFAOYSA-N C(CCCCCCC)C1=NC(=NO1)CC(C(=O)O)=C Chemical compound C(CCCCCCC)C1=NC(=NO1)CC(C(=O)O)=C TWSJVBWHYGITRA-UHFFFAOYSA-N 0.000 claims 1
• XEIGNNXGXDGYNS-UHFFFAOYSA-N C(CCCCCCC)C1=NN=C(O1)CC(C(=O)O)=C Chemical compound C(CCCCCCC)C1=NN=C(O1)CC(C(=O)O)=C XEIGNNXGXDGYNS-UHFFFAOYSA-N 0.000 claims 1
• MMAGLJSXIIPVQO-UHFFFAOYSA-N C(CCCCCCC)C1=NN=C(S1)CC(C(=O)O)=C Chemical compound C(CCCCCCC)C1=NN=C(S1)CC(C(=O)O)=C MMAGLJSXIIPVQO-UHFFFAOYSA-N 0.000 claims 1
• VKXQIGBREGDFAT-UHFFFAOYSA-N C(CCCCCCC)C=1N=C(SC=1)CC(C(=O)O)=C Chemical compound C(CCCCCCC)C=1N=C(SC=1)CC(C(=O)O)=C VKXQIGBREGDFAT-UHFFFAOYSA-N 0.000 claims 1
• GWOKLWPYRIQJQS-UHFFFAOYSA-N C(CCCCCCC)N1N=C(N=C1)CC(C(=O)O)=C Chemical compound C(CCCCCCC)N1N=C(N=C1)CC(C(=O)O)=C GWOKLWPYRIQJQS-UHFFFAOYSA-N 0.000 claims 1
• FGKVLVAQIQWODB-UHFFFAOYSA-N C1(CCC1)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 Chemical compound C1(CCC1)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 FGKVLVAQIQWODB-UHFFFAOYSA-N 0.000 claims 1
• QPGLOFRHORFOQL-UHFFFAOYSA-N C1(CCC1)OC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound C1(CCC1)OC1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C QPGLOFRHORFOQL-UHFFFAOYSA-N 0.000 claims 1
• OAOMEHCAOGHPBJ-UHFFFAOYSA-N C1(CCCC1)C1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound C1(CCCC1)C1=CC=C(C=C1)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C OAOMEHCAOGHPBJ-UHFFFAOYSA-N 0.000 claims 1
• FLYNELWIYBUFCK-UHFFFAOYSA-N C1(CCCC1)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 Chemical compound C1(CCCC1)C1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 FLYNELWIYBUFCK-UHFFFAOYSA-N 0.000 claims 1
• TVZVFXUCQNCCFG-UHFFFAOYSA-N C12(CC3CC(CC(C1)C3)C2)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound C12(CC3CC(CC(C1)C3)C2)C1=NOC(=N1)CC(C(=O)O)=C TVZVFXUCQNCCFG-UHFFFAOYSA-N 0.000 claims 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
• 208000022526 Canavan disease Diseases 0.000 claims 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
• 208000005024 Castleman disease Diseases 0.000 claims 1
• 208000002177 Cataract Diseases 0.000 claims 1
• 208000024699 Chagas disease Diseases 0.000 claims 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
• 208000002691 Choroiditis Diseases 0.000 claims 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
• NLMKPYLOAMYNKE-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound ClC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C NLMKPYLOAMYNKE-UHFFFAOYSA-N 0.000 claims 1
• CBATUDNPJKPQRV-UHFFFAOYSA-N ClC1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 Chemical compound ClC1=CC=C(CC2=NOC(=N2)CC(C(=O)O)=C)C=C1 CBATUDNPJKPQRV-UHFFFAOYSA-N 0.000 claims 1
• ZDUTZAOWLDYBHQ-UHFFFAOYSA-N ClC=1C=C(C=C(C=1)Cl)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound ClC=1C=C(C=C(C=1)Cl)C1(CC1)C1=NOC(=N1)CC(C(=O)O)=C ZDUTZAOWLDYBHQ-UHFFFAOYSA-N 0.000 claims 1
• PYGUHXITYWAKAO-UHFFFAOYSA-N ClC=1C=C(C=CC=1OC)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F Chemical compound ClC=1C=C(C=CC=1OC)C(C1=NOC(=N1)CC(C(=O)O)=C)(F)F PYGUHXITYWAKAO-UHFFFAOYSA-N 0.000 claims 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
• 208000010007 Cogan syndrome Diseases 0.000 claims 1
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
• 206010010252 Concentric sclerosis Diseases 0.000 claims 1
• 206010010356 Congenital anomaly Diseases 0.000 claims 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
• 108010036949 Cyclosporine Proteins 0.000 claims 1
• 201000003883 Cystic fibrosis Diseases 0.000 claims 1
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 1
• 108700036803 Deficiency of interleukin-1 receptor antagonist Proteins 0.000 claims 1
• 206010012434 Dermatitis allergic Diseases 0.000 claims 1
• 206010012438 Dermatitis atopic Diseases 0.000 claims 1
• 206010012442 Dermatitis contact Diseases 0.000 claims 1
• 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
• 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
• 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
• 241001475178 Dira Species 0.000 claims 1
• 208000021866 Dressler syndrome Diseases 0.000 claims 1
• 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 claims 1
• 201000002994 Dyschromatosis symmetrica hereditaria Diseases 0.000 claims 1
• 206010014561 Emphysema Diseases 0.000 claims 1
• 206010072378 Encephalitis autoimmune Diseases 0.000 claims 1
• 201000009273 Endometriosis Diseases 0.000 claims 1
• 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
• 206010015226 Erythema nodosum Diseases 0.000 claims 1
• 241000402754 Erythranthe moschata Species 0.000 claims 1
• 208000000289 Esophageal Achalasia Diseases 0.000 claims 1
• 208000004332 Evans syndrome Diseases 0.000 claims 1
• GLRHFRNMOQLEOG-UHFFFAOYSA-N FC(C1=NOC(=N1)CC(C(=O)O)=C)(C1=CC=C(C=C1)OC(F)(F)F)F Chemical compound FC(C1=NOC(=N1)CC(C(=O)O)=C)(C1=CC=C(C=C1)OC(F)(F)F)F GLRHFRNMOQLEOG-UHFFFAOYSA-N 0.000 claims 1
• HMXLSYJCVLTKFE-UHFFFAOYSA-N FC(C1=NOC(=N1)CC(C(=O)O)=C)(C1=CC=C(C=C1)SC(F)(F)F)F Chemical compound FC(C1=NOC(=N1)CC(C(=O)O)=C)(C1=CC=C(C=C1)SC(F)(F)F)F HMXLSYJCVLTKFE-UHFFFAOYSA-N 0.000 claims 1
• ZTHYLLMJAAMSNX-UHFFFAOYSA-N FC(CCCCC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F Chemical compound FC(CCCCC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F ZTHYLLMJAAMSNX-UHFFFAOYSA-N 0.000 claims 1
• YAGVWGWPRUNASB-UHFFFAOYSA-N FC(CCCCCC1=NOC(=N1)CC(C(=O)O)=C)(CC(F)(F)F)F Chemical compound FC(CCCCCC1=NOC(=N1)CC(C(=O)O)=C)(CC(F)(F)F)F YAGVWGWPRUNASB-UHFFFAOYSA-N 0.000 claims 1
• IRMDRDWDUUFUIM-UHFFFAOYSA-N FC(CCCCCCC)(F)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound FC(CCCCCCC)(F)C1=NOC(=N1)CC(C(=O)O)=C IRMDRDWDUUFUIM-UHFFFAOYSA-N 0.000 claims 1
• VSPBLQPWKKXTKQ-UHFFFAOYSA-N FC(CCCCCCC1=NOC(=N1)CC(C(=O)O)=C)(C)F Chemical compound FC(CCCCCCC1=NOC(=N1)CC(C(=O)O)=C)(C)F VSPBLQPWKKXTKQ-UHFFFAOYSA-N 0.000 claims 1
• IUDATCXVKMPRTD-UHFFFAOYSA-N FC(CCCCCCCC1=NOC(=N1)CC(C(=O)O)=C)F Chemical compound FC(CCCCCCCC1=NOC(=N1)CC(C(=O)O)=C)F IUDATCXVKMPRTD-UHFFFAOYSA-N 0.000 claims 1
• VWNSIAGXOAUZHR-UHFFFAOYSA-N FC(CCCCCCCCC1=NOC(=N1)CC(C(=O)O)=C)(F)F Chemical compound FC(CCCCCCCCC1=NOC(=N1)CC(C(=O)O)=C)(F)F VWNSIAGXOAUZHR-UHFFFAOYSA-N 0.000 claims 1
• YLIWWJYHVVJIRP-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)C1(CC1)C1=NC(=NO1)CC(C(=O)O)=C)(F)F Chemical compound FC(OC1=CC=C(C=C1)C1(CC1)C1=NC(=NO1)CC(C(=O)O)=C)(F)F YLIWWJYHVVJIRP-UHFFFAOYSA-N 0.000 claims 1
• GUNLHNSUSPRABD-UHFFFAOYSA-N FC(SC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F Chemical compound FC(SC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C)(F)F GUNLHNSUSPRABD-UHFFFAOYSA-N 0.000 claims 1
• 229940123457 Free radical scavenger Drugs 0.000 claims 1
• 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
• 208000010412 Glaucoma Diseases 0.000 claims 1
• 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
• 201000005569 Gout Diseases 0.000 claims 1
• 201000005708 Granuloma Annulare Diseases 0.000 claims 1
• 208000015023 Graves' disease Diseases 0.000 claims 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
• 208000001204 Hashimoto Disease Diseases 0.000 claims 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
• 206010019280 Heart failures Diseases 0.000 claims 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
• 208000005176 Hepatitis C Diseases 0.000 claims 1
• 208000009889 Herpes Simplex Diseases 0.000 claims 1
• 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
• 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 claims 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
• 101000962345 Homo sapiens NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 claims 1
• 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 1
• 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims 1
• 208000017731 Hypocomplementemic urticarial vasculitis Diseases 0.000 claims 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
• 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
• 208000031814 IgA Vasculitis Diseases 0.000 claims 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
• 206010021263 IgA nephropathy Diseases 0.000 claims 1
• 208000021330 IgG4-related disease Diseases 0.000 claims 1
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
• 208000037142 IgG4-related systemic disease Diseases 0.000 claims 1
• 108060003951 Immunoglobulin Proteins 0.000 claims 1
• 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims 1
• 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
• 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims 1
• 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims 1
• 108010005716 Interferon beta-1a Proteins 0.000 claims 1
• 108010005714 Interferon beta-1b Proteins 0.000 claims 1
• 102000003996 Interferon-beta Human genes 0.000 claims 1
• 108090000467 Interferon-beta Proteins 0.000 claims 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
• 102000000589 Interleukin-1 Human genes 0.000 claims 1
• 108010002352 Interleukin-1 Proteins 0.000 claims 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
• 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
• 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
• 206010022557 Intermediate uveitis Diseases 0.000 claims 1
• 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
• 208000000209 Isaacs syndrome Diseases 0.000 claims 1
• 208000032382 Ischaemic stroke Diseases 0.000 claims 1
• 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
• 206010024119 Left ventricular failure Diseases 0.000 claims 1
• 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
• 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
• 208000012309 Linear IgA disease Diseases 0.000 claims 1
• 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
• 208000000185 Localized scleroderma Diseases 0.000 claims 1
• 208000005777 Lupus Nephritis Diseases 0.000 claims 1
• 206010025280 Lymphocytosis Diseases 0.000 claims 1
• 208000004987 Macrophage activation syndrome Diseases 0.000 claims 1
• 208000001344 Macular Edema Diseases 0.000 claims 1
• 206010025415 Macular oedema Diseases 0.000 claims 1
• 208000009777 Majeed syndrome Diseases 0.000 claims 1
• 208000000932 Marburg Virus Disease Diseases 0.000 claims 1
• 208000030156 Marburg disease Diseases 0.000 claims 1
• 201000011013 Marburg hemorrhagic fever Diseases 0.000 claims 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims 1
• 206010069681 Monomelic amyotrophy Diseases 0.000 claims 1
• 208000024599 Mooren ulcer Diseases 0.000 claims 1
• 206010027982 Morphoea Diseases 0.000 claims 1
• 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 1
• 101710190051 Muscle, skeletal receptor tyrosine protein kinase Proteins 0.000 claims 1
• 102100038168 Muscle, skeletal receptor tyrosine-protein kinase Human genes 0.000 claims 1
• 208000021642 Muscular disease Diseases 0.000 claims 1
• 201000009623 Myopathy Diseases 0.000 claims 1
• 208000033214 Myopericarditis Diseases 0.000 claims 1
• 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 claims 1
• 208000032580 NMDA receptor encephalitis Diseases 0.000 claims 1
• 206010072359 Neuromyotonia Diseases 0.000 claims 1
• 206010058105 Neutrophilic dermatosis Diseases 0.000 claims 1
• 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 1
• CSQZBNKLLOMAFX-UHFFFAOYSA-N OC(C(C(=O)O)=C)C1=NC(=NO1)CCCCCCCC Chemical compound OC(C(C(=O)O)=C)C1=NC(=NO1)CCCCCCCC CSQZBNKLLOMAFX-UHFFFAOYSA-N 0.000 claims 1
• 208000008589 Obesity Diseases 0.000 claims 1
• 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 1
• 206010030136 Oesophageal achalasia Diseases 0.000 claims 1
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 1
• 208000003435 Optic Neuritis Diseases 0.000 claims 1
• 206010068786 Overlap syndrome Diseases 0.000 claims 1
• 206010070594 PFAPA syndrome Diseases 0.000 claims 1
• 239000012828 PI3K inhibitor Substances 0.000 claims 1
• 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
• 206010065311 Paraneoplastic retinopathy Diseases 0.000 claims 1
• 201000011152 Pemphigus Diseases 0.000 claims 1
• BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
• 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
• 208000031845 Pernicious anaemia Diseases 0.000 claims 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
• 208000000766 Pityriasis Lichenoides Diseases 0.000 claims 1
• 206010065159 Polychondritis Diseases 0.000 claims 1
• 208000025237 Polyendocrinopathy Diseases 0.000 claims 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
• 208000003971 Posterior uveitis Diseases 0.000 claims 1
• 208000004347 Postpericardiotomy Syndrome Diseases 0.000 claims 1
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
• 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
• 102000001708 Protein Isoforms Human genes 0.000 claims 1
• 108010029485 Protein Isoforms Proteins 0.000 claims 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
• 208000020193 Pulmonary artery hypoplasia Diseases 0.000 claims 1
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
• 206010063837 Reperfusion injury Diseases 0.000 claims 1
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
• 206010039085 Rhinitis allergic Diseases 0.000 claims 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
• 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
• 206010039705 Scleritis Diseases 0.000 claims 1
• 206010039710 Scleroderma Diseases 0.000 claims 1
• 208000034189 Sclerosis Diseases 0.000 claims 1
• 206010039811 Secondary amyloidosis Diseases 0.000 claims 1
• 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims 1
• 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
• 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 1
• 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 1
• 208000008950 Spondyloenchondrodysplasia Diseases 0.000 claims 1
• 208000026246 Spondyloenchondrodysplasia with immune dysregulation Diseases 0.000 claims 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
• 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 1
• 102100035533 Stimulator of interferon genes protein Human genes 0.000 claims 1
• 208000002286 Susac Syndrome Diseases 0.000 claims 1
• 210000001744 T-lymphocyte Anatomy 0.000 claims 1
• 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
• 206010071574 Testicular autoimmunity Diseases 0.000 claims 1
• 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
• 206010051526 Tolosa-Hunt syndrome Diseases 0.000 claims 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
• 208000029265 Type 1 interferonopathy Diseases 0.000 claims 1
• 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
• 208000025851 Undifferentiated connective tissue disease Diseases 0.000 claims 1
• 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 claims 1
• 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
• 229930003316 Vitamin D Natural products 0.000 claims 1
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
• 206010047642 Vitiligo Diseases 0.000 claims 1
• 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 claims 1
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
• SHKXYZFPAUNWJH-NSHDSACASA-N [C@H](C)(CC)OC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C Chemical compound [C@H](C)(CC)OC1=CC=C(C=C1)C1=NOC(=N1)CC(C(=O)O)=C SHKXYZFPAUNWJH-NSHDSACASA-N 0.000 claims 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
• 201000000621 achalasia Diseases 0.000 claims 1
• 208000027093 acute inflammatory demyelinating polyradiculoneuropathy Diseases 0.000 claims 1
• 206010064930 age-related macular degeneration Diseases 0.000 claims 1
• 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
• 201000010105 allergic rhinitis Diseases 0.000 claims 1
• 208000004631 alopecia areata Diseases 0.000 claims 1
• QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 claims 1
• 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
• 208000029188 anti-NMDA receptor encephalitis Diseases 0.000 claims 1
• 230000002280 anti-androgenic effect Effects 0.000 claims 1
• 239000000051 antiandrogen Substances 0.000 claims 1
• 208000002399 aphthous stomatitis Diseases 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 230000003143 atherosclerotic effect Effects 0.000 claims 1
• 230000007214 atherothrombosis Effects 0.000 claims 1
• 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
• 208000001974 autoimmune enteropathy Diseases 0.000 claims 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
• 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
• 208000006424 autoimmune oophoritis Diseases 0.000 claims 1
• 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 claims 1
• 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
• 208000029407 autoimmune urticaria Diseases 0.000 claims 1
• 230000005784 autoimmunity Effects 0.000 claims 1
• 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims 1
• 208000025255 bacterial arthritis Diseases 0.000 claims 1
• 230000003115 biocidal effect Effects 0.000 claims 1
• 210000000133 brain stem Anatomy 0.000 claims 1
• 125000001246 bromo group Chemical group Br* 0.000 claims 1
• 201000003848 bronchiolitis obliterans Diseases 0.000 claims 1
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 1
• 206010006451 bronchitis Diseases 0.000 claims 1
• 208000000594 bullous pemphigoid Diseases 0.000 claims 1
• 229940046731 calcineurin inhibitors Drugs 0.000 claims 1
• 208000014361 cancer-associated retinopathy Diseases 0.000 claims 1
• 229910052799 carbon Inorganic materials 0.000 claims 1
• 229910002091 carbon monoxide Inorganic materials 0.000 claims 1
• 125000006244 carboxylic acid protecting group Chemical group 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 239000003054 catalyst Substances 0.000 claims 1
• 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
• 238000006243 chemical reaction Methods 0.000 claims 1
• 208000029771 childhood onset asthma Diseases 0.000 claims 1
• 229960004630 chlorambucil Drugs 0.000 claims 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
• 229960003677 chloroquine Drugs 0.000 claims 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
• 208000002849 chondrocalcinosis Diseases 0.000 claims 1
• 208000007451 chronic bronchitis Diseases 0.000 claims 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
• 208000024376 chronic urticaria Diseases 0.000 claims 1
• 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
• 229960001265 ciclosporin Drugs 0.000 claims 1
• 229960002436 cladribine Drugs 0.000 claims 1
• WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims 1
• 229960004287 clofazimine Drugs 0.000 claims 1
• 229960001338 colchicine Drugs 0.000 claims 1
• 230000024203 complement activation Effects 0.000 claims 1
• 208000010247 contact dermatitis Diseases 0.000 claims 1
• 239000003246 corticosteroid Substances 0.000 claims 1
• 229960001334 corticosteroids Drugs 0.000 claims 1
• 230000000139 costimulatory effect Effects 0.000 claims 1
• 229940111134 coxibs Drugs 0.000 claims 1
• 201000003278 cryoglobulinemia Diseases 0.000 claims 1
• 125000000753 cycloalkyl group Chemical group 0.000 claims 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
• 229960004397 cyclophosphamide Drugs 0.000 claims 1
• 229930182912 cyclosporin Natural products 0.000 claims 1
• 230000006378 damage Effects 0.000 claims 1
• 229960000860 dapsone Drugs 0.000 claims 1
• 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
• 230000000779 depleting effect Effects 0.000 claims 1
• 238000010511 deprotection reaction Methods 0.000 claims 1
• 201000001981 dermatomyositis Diseases 0.000 claims 1
• 201000011190 diabetic macular edema Diseases 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 201000004997 drug-induced lupus erythematosus Diseases 0.000 claims 1
• 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
• 208000019479 dysautonomia Diseases 0.000 claims 1
• 201000002491 encephalomyelitis Diseases 0.000 claims 1
• 208000037902 enteropathy Diseases 0.000 claims 1
• 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
• 125000004185 ester group Chemical group 0.000 claims 1
• 208000033699 familial Guillain-Barre syndrome Diseases 0.000 claims 1
• 208000008805 familial cylindromatosis Diseases 0.000 claims 1
• 229940125753 fibrate Drugs 0.000 claims 1
• 125000001153 fluoro group Chemical group F* 0.000 claims 1
• 108020001507 fusion proteins Proteins 0.000 claims 1
• 102000037865 fusion proteins Human genes 0.000 claims 1
• 229940042385 glatiramer Drugs 0.000 claims 1
• 239000003862 glucocorticoid Substances 0.000 claims 1
• 150000002344 gold compounds Chemical class 0.000 claims 1
• 125000005842 heteroatom Chemical group 0.000 claims 1
• 208000002557 hidradenitis Diseases 0.000 claims 1
• 201000007162 hidradenitis suppurativa Diseases 0.000 claims 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
• 229960004171 hydroxychloroquine Drugs 0.000 claims 1
• 230000002519 immonomodulatory effect Effects 0.000 claims 1
• 230000008938 immune dysregulation Effects 0.000 claims 1
• 102000018358 immunoglobulin Human genes 0.000 claims 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
• 238000009169 immunotherapy Methods 0.000 claims 1
• 201000008319 inclusion body myositis Diseases 0.000 claims 1
• 208000021319 infantile-onset periodic fever-panniculitis-dermatosis syndrome Diseases 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 102000006495 integrins Human genes 0.000 claims 1
• 108010044426 integrins Proteins 0.000 claims 1
• 229960004461 interferon beta-1a Drugs 0.000 claims 1
• 229960003161 interferon beta-1b Drugs 0.000 claims 1
• 229960001388 interferon-beta Drugs 0.000 claims 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
• 208000028774 intestinal disease Diseases 0.000 claims 1
• 230000000968 intestinal effect Effects 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
• GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
• 229960004577 laquinimod Drugs 0.000 claims 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
• 229960000681 leflunomide Drugs 0.000 claims 1
• 201000001996 leukoencephalopathy with vanishing white matter Diseases 0.000 claims 1
• 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
• 201000011486 lichen planus Diseases 0.000 claims 1
• 208000010325 limbic encephalitis Diseases 0.000 claims 1
• 208000006132 lipodystrophy Diseases 0.000 claims 1
• 206010025135 lupus erythematosus Diseases 0.000 claims 1
• 230000000527 lymphocytic effect Effects 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 claims 1
• 201000010230 macular retinal edema Diseases 0.000 claims 1
• 230000001404 mediated effect Effects 0.000 claims 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
• 229910052751 metal Inorganic materials 0.000 claims 1
• 239000002184 metal Substances 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 229960000485 methotrexate Drugs 0.000 claims 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
• 208000008275 microscopic colitis Diseases 0.000 claims 1
• 208000012268 mitochondrial disease Diseases 0.000 claims 1
• 230000002438 mitochondrial effect Effects 0.000 claims 1
• 229950000844 mizoribine Drugs 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 239000000472 muscarinic agonist Substances 0.000 claims 1
• 206010028417 myasthenia gravis Diseases 0.000 claims 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
• 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
• 229960000951 mycophenolic acid Drugs 0.000 claims 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 201000003631 narcolepsy Diseases 0.000 claims 1
• 230000002956 necrotizing effect Effects 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 208000015122 neurodegenerative disease Diseases 0.000 claims 1
• 208000008795 neuromyelitis optica Diseases 0.000 claims 1
• 230000003472 neutralizing effect Effects 0.000 claims 1
• 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
• 235000020824 obesity Nutrition 0.000 claims 1
• ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 claims 1
• 229960001601 obeticholic acid Drugs 0.000 claims 1
• 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims 1
• 201000005737 orchitis Diseases 0.000 claims 1
• 201000010846 otulipenia Diseases 0.000 claims 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
• 201000005580 palindromic rheumatism Diseases 0.000 claims 1
• 201000007407 panuveitis Diseases 0.000 claims 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 claims 1
• 230000037361 pathway Effects 0.000 claims 1
• 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
• 229960001476 pentoxifylline Drugs 0.000 claims 1
• 208000025487 periodic fever syndrome Diseases 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1
• 239000000825 pharmaceutical preparation Substances 0.000 claims 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
• 238000001126 phototherapy Methods 0.000 claims 1
• 229960003073 pirfenidone Drugs 0.000 claims 1
• ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
• 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
• 208000005987 polymyositis Diseases 0.000 claims 1
• 230000002980 postoperative effect Effects 0.000 claims 1
• 229940125422 potassium channel blocker Drugs 0.000 claims 1
• 239000003450 potassium channel blocker Substances 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 208000018290 primary dysautonomia Diseases 0.000 claims 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
• 230000000750 progressive effect Effects 0.000 claims 1
• 235000019260 propionic acid Nutrition 0.000 claims 1
• 239000003207 proteasome inhibitor Substances 0.000 claims 1
• 230000018883 protein targeting Effects 0.000 claims 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
• 150000003212 purines Chemical class 0.000 claims 1
• 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
• 239000002516 radical scavenger Substances 0.000 claims 1
• 238000001959 radiotherapy Methods 0.000 claims 1
• 208000002574 reactive arthritis Diseases 0.000 claims 1
• 229940075993 receptor modulator Drugs 0.000 claims 1
• 208000009169 relapsing polychondritis Diseases 0.000 claims 1
• 208000019745 retinal vasculopathy with cerebral leukodystrophy Diseases 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 206010039083 rhinitis Diseases 0.000 claims 1
• 229960004181 riluzole Drugs 0.000 claims 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
• 229960001860 salicylate Drugs 0.000 claims 1
• 201000000306 sarcoidosis Diseases 0.000 claims 1
• 201000000980 schizophrenia Diseases 0.000 claims 1
• 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
• 201000009890 sinusitis Diseases 0.000 claims 1
• 150000003410 sphingosines Chemical class 0.000 claims 1
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
• 150000003431 steroids Chemical class 0.000 claims 1
• 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
• 238000002626 targeted therapy Methods 0.000 claims 1
• UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 1
• 229960000331 teriflunomide Drugs 0.000 claims 1
• 229960003433 thalidomide Drugs 0.000 claims 1
• 229960000278 theophylline Drugs 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 208000008732 thymoma Diseases 0.000 claims 1
• 208000009174 transverse myelitis Diseases 0.000 claims 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
• 235000019166 vitamin D Nutrition 0.000 claims 1
• 239000011710 vitamin D Substances 0.000 claims 1
• 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
• 229940046008 vitamin d Drugs 0.000 claims 1
• 208000005494 xerophthalmia Diseases 0.000 claims 1